Ashland has launched iSolveSM information on demand to support food and beverage customers. It is a portal with easy access to robust information about the company’s food and beverage ingredients and other important related business material such as our most recent innovations, literature, formulations, products, and regulatory documents and more.
Ashland is introducing Polyplasdone Plus, a co-processed multifunctional direct compression superdisintegrant containing a glidant and lubricant. Saving time and simplifying development, the multifunctional disintegrant offers superior powder flow and lubrication during pharmaceutical manufacturing. This innovative product eliminates two manufacturing steps and simplifies equipment setup while simultaneously delivering improved tablet hardness and helping ensure the production of consistent, high-quality products in batch and continuous manufacturing.
Ashland’s life sciences laboratory in Hyderabad, India has attained ISO 17025:2017 certification, an international standard for laboratory management that sets the requirements for a laboratory's competence, impartiality, and consistent operation.
Ashland announced the United States Food and Drug Administration (FDA) Center for Drug Evaluation and Research Office of New Drugs has accepted Ashland Viatel bioresorbable mPEG-PDLLA pharmaceutical excipient in the review cycle of the FDA Novel Excipient Review Pilot Program.
Ashland has agreed to acquire New Jersey-based Pharmachem Laboratories, a manufacturer of supplements and specialty ingredients for the wellness and personal care industries, for $660 million in cash.
Ashland has opened a pharmaceutical excipients plant in Nanjing, China in a bid to capture growing local demand for modern formulation technologies.